AMA President, Susan R. Bailey, MD and the AMA Director of Science and Drug Policy, Amy B. Cadwallader, PhD presented a session at the 2021 Rx Drug Abuse & Heroin Summit that highlighted the reasons why data standardization and public health interventions have been elusive and they provide actionable solutions for states, organizations, and policymakers to meaningfully address the nation’s overdose epidemic.
American Medical Association
Updated April 15, 2021.
This issue brief is focused on positive interventions that are working to help increase access to evidence-based treatment for substance use disorders, patients with pain and harm reduction efforts. The reports include news releases, data from multiple and varied sources, including national, state and local public health agencies, advocacy organizations, law enforcement, emergency medical services, hospitals, treatment centers, research journals and others.
AMA resource details numerous state parity violations and provides specific recommendations for meaningful oversight and enforcement.
New issue brief shows broad use of increased DEA prescribing and treatment flexibility; barriers and concerns, however, persist.
This issue brief summarizes the findings of a recent AMA, Colorado Medical Society, Colorado Pain Society and Manatt Health report submitted to the Colorado Division of Insurance in support of multidisciplinary, multimodal pain care.
The American Medical Association, Colorado Medical Society, Colorado Pain Society and Manatt Health worked with Oliver Wyman to provide a detailed Request for Information to the Colorado Division of Insurance on the costs associated with the health coverage provisions proposed in Colorado House Bill 20-1085 that would have increased access to multidisciplinary, multimodal pain care.